RecruitingNCT05837663
Trifecta-Lung cfDNA-MMDx Study
Trifecta-Lung cfDNA-MMDx Study: Comparing the Dd-cfDNA Test to MMDx Microarray Test and Central HLA Antibody Test
Sponsor
University of Alberta
Enrollment
600 participants
Start Date
Nov 1, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
Demonstrate the relationship between dd-cfDNA levels and HLA antibodies in blood transplant recipient and Demonstrate the Molecular Microscope® (MMDx) Diagnostic System results in indication and protocol biopsies from lung transplants.
Eligibility
Min Age: 18 Years
Inclusion Criteria1
- Adult, Older adult
Exclusion Criteria1
- Patients will be excluded from the study if they decline participation Are unable to give informed consent. Recipients of multiple organs, cancer patients and pregnant women
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(19)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05837663
Related Trials
Risk Factors That Increase the Chance of Developing Primary Graft Dysfunction After Lung Transplantation
NCT005523571 location
LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.
NCT060187661 location
This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction
NCT068532231 location
Long-term Follow-up of the Offspring Born to Mothers With a Solid Organ Transplant, Transplantlines Next Generation
NCT072912581 location
Identifying Genetic Characteristics That Increase Risk of Primary Graft Dysfunction Following Lung Transplantation
NCT004578471 location